The Craigslist ad was practical. Brian Slingerland had recently arrived in Palo Alto, fresh from Virginia Tech and starting work as an investment-banking analyst. He needed someone to share an apartment. Scott Dylla, a cancer researcher at Stanford, replied. The arrangement went nowhere. The conversation did not.
They became friends, then regulars in coffee shops, where Dylla explained a theory about cancer stem cells and Slingerland kept asking the sort of questions bankers are paid to ask: What would it take to prove this? How long would it take? Who would fund it? The accidental introduction became a six-year education. In 2008, the two formed Stemcentrx in South San Francisco.
There is a tidy version of this story in which fate places the correct scientist in front of the correct finance graduate. The more useful version is untidy. Slingerland did not understand the science when they met. He spent years learning it. He did not arrive with a laboratory. He arrived with an ability to turn a proposal into a plan with a budget, a timeline, goals, and a pitch that other people could believe without suspending arithmetic.
The business mind at the lab bench
Slingerland's route into biotechnology began in finance. He graduated from Virginia Tech's Pamplin College of Business in 2000, moved west for Credit Suisse First Boston, and later joined Goldman Sachs. By early 2008 he had risen to managing director. Then he resigned and co-founded two companies in the same year.
One was Qatalyst Partners, the technology-focused investment bank built with Frank Quattrone and other dealmakers. The other was Stemcentrx. It is an odd pairing only if the categories on a résumé are mistaken for a personality. Both enterprises asked Slingerland to organize people, capital, judgment, and timing around complicated bets. One lived in conference rooms. The other required freezers, assays, manufacturing, and clinical trials.
At Stemcentrx, complementary skill was the point. Dylla brought the scientific program. Slingerland brought company formation, financing, and the habit of forcing an idea into operational form. The company went on to build capabilities in target discovery and validation, manufacturing, and clinical development. It also established partnerships with Pfizer and Bristol Myers Squibb.
“The best ventures have a sound balance of technical and business skill.”Brian Slingerland, Virginia Tech commencement, 2016
That sentence is both advice and autobiography. The popular founder myth rewards the person with the breakthrough in the notebook. Slingerland's career makes room for another kind of founder: the translator who respects the notebook, learns its language, and constructs the institution around it. Translation sounds modest. Done properly, it includes recruiting, fundraising, priorities, culture, and knowing which deadline is real.
The long work behind the large number
Stemcentrx operated for eight years before AbbVie announced its acquisition in April 2016. The upfront transaction was approximately $5.8 billion in cash and stock. Former holders could receive up to $4 billion more if specified clinical and regulatory milestones were achieved. Add the company's cash and the possible value was widely described at the time as $10.2 billion.
The bars show relative announced amounts, not payments ultimately received. The second figure depended on clinical and regulatory achievements.
The number deserves its asterisk. Drug development does not respect the closing-day mood. In 2019, AbbVie ended the research program for Rova-T, Stemcentrx's lead compound, after a Phase 3 trial showed no survival benefit against placebo at an interim analysis. It is an essential part of the record: a company can be acquired at an arresting valuation while the underlying experiment remains unresolved.
That complication makes Slingerland's earlier patience more interesting, not less. Biotechnology deals can move ownership. Only evidence settles biology. The executive's job is to create enough time, money, talent, and rigor for that evidence to appear. Sometimes the answer is unwelcome. A serious account of company-building has to leave room for the lab to say no.
Graduates from Virginia Tech in finance and begins at Credit Suisse First Boston in California.
Leaves Goldman Sachs and co-founds Qatalyst Partners and Stemcentrx.
AbbVie completes the Stemcentrx acquisition; Slingerland addresses Pamplin graduates.
Leads Convergent Genomics and serves on the Link Cell Therapies board.
Make the avocation the vocation
Slingerland told Virginia Tech graduates to align their passion and personal mission with their work. “Make your avocation your vocation,” he said. He also warned that maintaining the status quo would often look tempting. Coming from someone who left a managing-director position to start both an investment bank and a biotechnology company, the line carried receipts.
His entrepreneurial instinct appeared much earlier. At 10, growing up in Syracuse, New York, he ran a lawn-mowing business that, as he later joked, captured strong market share in the neighborhood. The language is charmingly overqualified for grass. The pleasure beneath it is plain: he liked making a little system work.
His commencement advice also put relationships inside the founder story. Choose a life partner and friends who offer honest counsel, he told the graduates. While he was pitching investors and recruiting Stemcentrx's first employees, he credited his wife, Emily, his parents, and close friends with supplying confidence behind the scenes. The supposedly solitary leap had a crowded backstage.
Pair the skills
Technical depth and business judgment should reinforce each other.
Make work matter
Connect daily work to a mission strong enough to sustain a long career.
Keep candid company
Build around people willing to encourage you and tell you the truth.
One anecdote sharpens the point. In late 2011, investor Brian Singerman met Slingerland near his home and invited him to a gathering at Peter Thiel's house that same evening. It was Slingerland's first wedding anniversary. He hesitated, then went, spending the night discussing cancer stem cells with potential backers. The story is funny because the names are similar and the timing is dreadful. It also shows how early companies are assembled: conviction, inconvenience, and one more conversation than a sensible calendar allows.
A second pass at the problem
Today Slingerland is chief executive of Convergent Genomics, another South San Francisco company working where genomic data meets clinical practice. Its UroAmp test analyzes DNA from urine using next-generation sequencing and machine-learning methods. The company says its platform measures 250,000 genomic locations, deeply examines 60 genes, and produces information intended to help detect and monitor urothelial cancer.
The role is familiar even if the product is different. Scientists, clinicians, data specialists, and operators have to agree on what the evidence means and how it becomes a usable test. The work is less cinematic than an acquisition announcement. It is validation, laboratory standards, observational cohorts, regulatory language, and the small humiliations involved in making a complicated process repeatable.
Slingerland also sits on the board of Link Cell Therapies. The company emerged from stealth in December 2025 with a $60 million Series A and a focus on cell therapies. His board biography emphasizes the same bridge he has crossed for years: early banking work on financings, public offerings, partnerships, and acquisitions; the founding of Qatalyst; then the construction of a biotechnology company able to discover targets and move programs toward the clinic.
The operator's recurring pattern
Across those roles, Slingerland's method has three visible parts. First, choose a technical problem large enough to justify a long effort. Second, work with people whose expertise is genuinely different from his own. Third, give the work a commercial and organizational frame. The pattern sounds orderly when listed. In practice, each part contains friction. Technical teams can resent financial constraints. Investors can become impatient with experimental timelines. A founder fluent in only one side can make the other side feel like an interruption.
His banking background offered useful equipment for the middle. An adviser learns to hold several versions of the future at once, attach numbers to them, and explain the tradeoffs to people with different incentives. A biotech executive has to do that while accepting a further indignity: the most important outcome may be controlled by an experiment no negotiation can improve. Finance can ration risk. It cannot persuade a molecule.
That boundary helps explain why Slingerland's language returns to mission and culture. A plan can tell a team what to do next. It cannot, on its own, make talented people endure years of ambiguity. He has described a manager's early duties as setting a clear, meaningful mission and plan that motivate the team, drive priorities, and measure progress. The adjectives matter. Clear without meaningful produces compliance. Meaningful without clear produces a handsome poster and a confused Monday morning.
His current portfolio also resists the usual neat founder ending. There was no permanent retirement after the sale, no conversion into a public oracle. Convergent Genomics returned him to a focused diagnostic company. Link Cell Therapies put him in a governance role beside scientists, investors, and experienced drug developers. Both positions use history as working material rather than a trophy. The lesson from an earlier company is valuable only when it changes the questions asked at the next one.
A classified ad explains none of that by itself. Chance supplied an introduction. Curiosity turned it into an apprenticeship. Complementary talent turned it into a company. The most stealable idea in Slingerland's story is not to wait for a miraculous roommate. It is to notice when somebody knows what you do not, and to stay in the conversation long enough to build something neither of you could build alone.